19 April 2024
19 April 2024
The latest approval is based on findings from the Phase III VISIBLE 2 Study.
AskBio is enrolling participants in the Phase II GenePHIT trial of AB-1002, focusing on the treatment of CHF.
OncoX will pay an upfront cost of $12.5m in cash and shares for rights to ABVC’s non-small cell lung cancer therapy, BLEX 404.
The deal comprises an option to assess separate nephrology targets using human multi-omics data.
Alchemab CSO Jane Osbourn also observes recent ‘step change’ in collaboration and consortia around dementia.
For the process, the researchers employed a machine learning method called transfer learning.
Higher CCL24 levels in systemic sclerosis patients have been linked to more severe forms of the condition.
At the ongoing Diabetes UK conference, experts highlighted the potential benefits and concerns surrounding weekly insulin candidates.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
